Erythrocyte depletion lifts nanoparticle half-lives

The partial depletion of red blood cells via the administration of a low dose of anti-erythrocyte antibodies increases the circulation half-life of nanomedicines, as shown in rodent models of cancer.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Fig. 1: The depletion of RBCs via a small dose of anti-erythrocyte antibody that partially blocks the MPS extends the bioavailability of intravenously injected nanoparticles.


  1. 1.

    Nel, A. et al. Nat. Mater. 8, 543–557 (2009).

    CAS  Article  Google Scholar 

  2. 2.

    Cabral, H., Miyata, K., Osada, K. & Kataoka, K. Chem. Rev. 118, 6844–6892 (2018).

    CAS  Article  Google Scholar 

  3. 3.

    Hu, C.-M. J. et al. Nature 526, 118–121 (2015).

    CAS  Article  Google Scholar 

  4. 4.

    Sarett, S. M. et al. Proc. Natl Acad. Sci. USA 114, E6490–E6497 (2017).

    CAS  Article  Google Scholar 

  5. 5.

    Anselmo, A. C. et al. ACS Nano 7, 11129–11137 (2013).

    CAS  Article  Google Scholar 

  6. 6.

    Proffitt, R. et al. Science 220, 502–505 (1983).

    CAS  Article  Google Scholar 

  7. 7.

    Nikitin, M. P. et al. Nat. Biomed. Eng. (2020).

    Article  PubMed  Google Scholar 

  8. 8.

    Lundqvist, M. et al. Proc. Natl Acad. Sci. USA 105, 14265–14270 (2008).

    CAS  Article  Google Scholar 

Download references

Author information



Corresponding authors

Correspondence to Horacio Cabral or Kazunori Kataoka.

Ethics declarations

Competing interests

K.K. is scientific advisor of NanoCarrier. The remaining author declares no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Cabral, H., Kataoka, K. Erythrocyte depletion lifts nanoparticle half-lives. Nat Biomed Eng 4, 670–671 (2020).

Download citation